Advertisement
Canada markets close in 4 hours 46 minutes

  • S&P/TSX

    21,870.46
    -141.26 (-0.64%)
     

  • S&P 500

    5,059.70
    -10.85 (-0.21%)
     

  • DOW

    38,360.84
    -142.85 (-0.37%)
     

  • CAD/USD

    0.7286
    -0.0035 (-0.47%)
     

  • CRUDE OIL

    82.83
    -0.53 (-0.64%)
     

  • Bitcoin CAD

    89,321.38
    -2,342.08 (-2.56%)
     

  • CMC Crypto 200

    1,406.19
    -17.91 (-1.26%)
     

  • GOLD FUTURES

    2,350.00
    +7.90 (+0.34%)
     

  • RUSSELL 2000

    1,994.52
    -8.13 (-0.41%)
     

  • 10-Yr Bond

    4.6620
    +0.0640 (+1.39%)
     

  • NASDAQ

    15,713.81
    +17.17 (+0.11%)
     

  • VOLATILITY

    15.96
    +0.27 (+1.72%)
     

  • FTSE

    8,039.16
    -5.65 (-0.07%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6815
    -0.0021 (-0.31%)
     
MARKETS LIVE BLOG:

STOCKS TRADE MIXED, TESLA SURGES DAY AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

CannabisNewsAudio Announces Audio Press Release (APR) on Lexaria Bioscience Corp. Innovative Cannabinoid Applications

Newsfile Corp.
Updated

New York, New York--(Newsfile Corp. - April 5, 2018) - CannabisNewsAudio announces the Audio Press Release (APR) titled "Infusion of Biotechnology into Cannabis Market Leads to Booming Growth," featuring Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX).

To hear the NetworkNewsAudio version, visit: http://nnw.fm/jhN9b

To read the original editorial, visit: http://cnw.fm/prTG5

The company is also exploring the use of DehydraTECH in the absorption of drugs through the skin. Lexaria has recently filed a new patent to improve the speed and quantity of absorption for transdermal applications (http://cnw.fm/4sYzF). A recent breakthrough in testing discovered that DehydraTECH can double the transdermal absorption of cannabidiol compared with leading commercial alternatives. This will allow the company to newly license its technology to create improved patches, creams, cosmetics and more.

In addition, the company's work has been enhanced through an R&D agreement with the Canadian government's National Research Council. This agreement is expected to result in a better understanding of how Lexaria's technology works, leading to more agreements with other businesses.

It is ironic that this technology was developed for the cannabis industry but has already received patent protection for many other commonly used drugs. Anti-inflammatory drugs, vitamins and nicotine could all be deployed using Lexaria's disruptive technology. Supplements, pain relief and smoking-cessation or smoking-alternative nicotine products are all possible as a result of Lexaria's research. To this end, the company recently commenced a study into nicotine absorption (http://cnw.fm/DLo69). Who would have thought that cannabis research might lead to broader biotechnology applications that could benefit non-cannabis consumers?

ADVERTISEMENT

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive patented technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit www.LexariaBioscience.com

About CannabisNewsWire (CNW)

CannabisNewsWire ("CNW") is a specialized information service that (1) aggregates cannabis news, (2) provides CannabisNewsBreaks that quickly updates investors in the space, (3) enhances corporate press releases, (4) helps companies with distribution and optimization of social media, and (5) delivers comprehensive corporate communication solutions. CNW is uniquely positioned in the cannabis market with a strong team of journalists and writers who can help private and public companies reach a wide audience of investors, consumers, journalists and the general public through our ever-growing dissemination network of more than 5,000 key syndication outlets. CNW is bringing unparalleled visibility, recognition and content to the cannabis industry.

For more information please visit https://wwwCannabisNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://CNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

CNW Corporate Communications Contact:

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net